25 of the Best Neurologists Near Me in Bowie, MD

Dr. Alexander Pantelyat cares for patients with movement disorders such as Parkinson's disease and related syndromes, essential tremor, dystonia, chorea and normal pressure hydrocephalus. He also provides botulinum toxin injections for movement disorders and is involved in deep brain stimulation programming and intraoperative neurophysiological monitoring.His research explores atypical parkinsonian disorders, such as dementia with Lewy bodies, progressive supranuclear palsy, corticobasal syndrome/degeneration and multiple system atrophy; cognitive aspects of movement disorders; and music-based rehabilitation of neurodegenerative diseases.Dr. Pantelyat earned his medical degree from Temple University School of Medicine in Philadelphia, where he was elected a member of the Alpha Omega Alpha Honor Medical Society and received the Matthew T. Moore Prize in Neurology. He completed his residency training in Neurology ​at the University of Pennsylvania in Philadelphia, and a fellowship in movement disorders at the University of Pennsylvania/Philadelphia VA Medical Center. As part of his fellowship, Dr. Pantelyat also completed the Clinical Research Certificate Program at the Center for Clinical Epidemiology and Biostatistics. He is a 2013 American Academy of Neurology Palatucci Advocacy Leader and grant recipient. Dr. Pantelyat is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Progressive Supranuclear Palsy, Progressive Supranuclear Palsy Atypical, Supranuclear Ophthalmoplegia, and Movement Disorders.

Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy. Dr. Blakeley is board certified in American Board Of Psychiatry And Neurology.

Liana Rosenthal, M.D. is an Assistant Professor in the Department of Neurology at Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr. Rosenthal completed medical school at Johns Hopkins with an internship at Johns Hopkins Bayview Medical Center. She completed her neurology residency and movement disorder fellowship at The Johns Hopkins Hospital. Dr. Rosenthal is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Movement Disorders, Parkinson's Disease, Olivopontocerebellar Atrophy, and Spinocerebellar Ataxia. Dr. Rosenthal is board certified in American Board Of Psychiatry And Neurology.

Dr. Comi graduated from SUNY Buffalo School of Medicine and received her training in pediatrics at the Children's Hospital of Buffalo and her child neurology training at Johns Hopkins Medicine. Her clinical specialization is in the treatment of the neurological aspects of Sturge-Weber syndrome and other disorders related to capillary malformation. Dr. Comi's clinical research interests focus on improving the early diagnosis and treatment of brain involvement in Sturge-Weber syndrome in order to prevent ischemic brain injury in affected infants and young children, and on studies to understand what causes Sturge-Weber syndrome. Her laboratory research work deals with the pathogenesis of Sturge-Weber syndrome, recently shown to be caused by a somatic mutation, and on developing new drug targets, screening assays, models and therapeutic strategies for Sturge-Weber syndrome. Her lab group also works on developing better neuroprotective and neuroregenerative responses to brain injury resulting from impaired blood flow to the brain. Dr. Comi is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Sturge-Weber Syndrome, Parkes Weber Syndrome, Stork Bite, Epilepsy in Children, and Endovascular Embolization. Dr. Comi is board certified in American Board Of Psychiatry And Neurology.

Dr. Leung obtained her undergraduate degree in biochemical sciences from Harvard University. While attending medical school at Duke University, she completed a year-long research fellowship studying genetic markers of late-onset Alzheimer’s disease at the National Institute on Aging as part of the NIH Clinical Research Training Program. She completed her neurology residency and clinical neurophysiology fellowship at Stanford University Medical Center, and is currently a Ph.D. candidate in the graduate training program in clinical investigation at the Johns Hopkins Bloomberg School of Public Health. Dr. Leung joined the Center for Genetic Muscle Disorders at the Kennedy Krieger Institute as a translational research fellow in 2010 and was appointed to the faculty in 2014. Her clinic specializes in electromyography and the diagnosis and treatment of hereditary muscle diseases. Dr. Leung’s research focuses on the development of imaging biomarkers and outcome measures for muscle diseases. She is the principal investigator for a longitudinal cohort study of whole-body MRI in facioscapulohumeral muscular dystrophy. Dr. Leung is also a site principal investigator for the Ionis-DMPKRx trial, a phase Ib/IIa clinical trial of a novel RNA-based therapy for myotonic muscular dystrophy. Dr. Leung is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Facioscapulohumeral Muscular Dystrophy (FSHD), Limb-Girdle Muscular Dystrophy Type 2I, Limb-Girdle Muscular Dystrophy, and Dysferlinopathy. Dr. Leung is board certified in American Board Of Psychiatry And Neurology.

Dr. Michael Polydefkis focuses on neuromuscular diseases, particularly peripheral nerve diseases. He has a special interest in diabetic and HIV-associated peripheral neuropathy. His expertise includes nerve conduction studies, electromyography and nerve, skin and muscle biopsy reading. Dr. Michael Polydefkis received his medical degree from The Johns Hopkins University School of Medicine. He then became a Howard Hughes Medical Institute research fellow before returning to Johns Hopkins to complete an internship and residency in internal medicine, residency in neurology and a fellowship in neuromuscular diseases. Dr. Polydefkis is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Transthyretin Amyloidosis, Familial Transthyretin Amyloidosis, Primary Amyloidosis, and Peripheral Neuropathy.

Neurologist Scott Newsome specializes in the care of patients with neuroimmunological and neuroinflammatory disorders of the central nervous system. He works within the Division of Neuroimmunology and Neurological Infections at The Johns Hopkins Hospital, and has special interest in evaluating and treating patients with multiple sclerosis, transverse myelitis, neuromyelitis optica and stiff person syndrome. After completing fellowship training, Dr. Newsome joined the Johns Hopkins Multiple Sclerosis and Transverse Myelitis Centers, and he is the director of the Johns Hopkins Neurosciences Consultation and Infusion Center and the Stiff Person Syndrome Center. He is also director of the Johns Hopkins Neuroimmunology and Neurological Infectious Disease Fellowship Program and co-director of the Multiple Sclerosis Experimental Therapeutics Program. Dr. Newsome received his medical degree from the New York College of Osteopathic Medicine, with honors. During his neurology residency, he was awarded the Golden Apple Outstanding Resident Teaching Award, and later was chosen to be chief resident. He subsequently completed a fellowship in neuroimmunology at The Johns Hopkins Hospital with the support of a Sylvia Lawry Physician Fellowship Award from the National Multiple Sclerosis Society. Identifying and testing novel therapies and therapeutic strategies for multiple sclerosis and other neuroimmunological disorders is Dr. Newsome’s main research focus. Other research endeavors include validating the use of new quantitative clinical outcome measures and imaging techniques in multiple sclerosis and identifying risk factors of disease onset and severity, response to treatment and long-term outcomes in neuroimmunological disorders. An adviser for the National Multiple Sclerosis Society and a member of the Miller-Coulson Academy of Clinical Excellence, Dr. Newsome has also served as president of the Consortium of Multiple Sclerosis Centers. Dr. Newsome is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Stiff Person Syndrome, Multiple Sclerosis (MS), Transverse Myelitis, and Relapsing Multiple Sclerosis (RMS). Dr. Newsome is board certified in American Board Of Psychiatry And Neurology.

Dr. Peter Kaplan is Professor of Neurology and serves as the Director of Epilepsy and EEG at Johns Hopkins Bayview Medical Center. He focuses on epilepsy, clinical neurophysiology and nonconvulsive status epilepticus. He has written extensively about these subjects as well as about eclampsia and neurologic disease in women. Dr. Peter Kaplan received his medical training from St. Bartholomews Medical School, University of London. He then obtained membership to the Royal College of Physicians in England. He completed his residency in neurology at Duke University Medical Center. He completed fellowships in epilepsy and clinical neurophysiology at the same institution. Dr. Kaplan currently sees patients at the Johns Hopkins Bayview Medical Center on Tuesdays and Wednesdays. Dr. Kaplan is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Seizures, Generalized Tonic-Clonic Seizure, Status Epilepticus, Epilepsy, and Awake Craniotomy. Dr. Kaplan is board certified in American Board Of Psychiatry And Neurology.

Dr. Ahmet Hoke is Professor of Neurology and Neuroscience, W. W. Smith Charitable Trust Professor of Neuroimmunology at Johns Hopkins School of Medicine, Director of the Daniel B. Drachman Division of Neuromuscular Diseases and Director of the Merkin Peripheral Neuropathy and Nerve Regeneration Center at Johns Hopkins University School of Medicine. He completed his medical training at Hacettepe University School of Medicine in Ankara, Turkey followed by his PhD studies in developmental neuroscience at Case Western Reserve University in Cleveland, Ohio, and neurology residency at Johns Hopkins Hospital. After completing his neuromuscular training at University of Calgary, Canada, he returned to Johns Hopkins University as faculty and rose through the ranks. He is the recipient of several awards including Derek Denny Brown Young Neurological Scholar Award (2005) and Wolfe Neuropathy Research prize (2018) given by the American Neurological Association, Myung Memorial Lecture Award (2017) by the Korean Neurological Association, Nejat Eczacibasi Medical Scientist Award (2019) by the Eczacibasi Foundation, Turkey, and Alan J. Gebhart Prize in Excellence in Neuropathy Research (2022) by the Peripheral Nerve Society. He is an Ex-Officio member of the Board of Directors of the American Neurological Association, and Vice-President of the Toxic Neuropathy Consortium. He serves on several editorial boards and is the Editor-in-Chief of Annals of Clinical and Translational Neurology. Dr. Hoke is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Wallerian Degeneration, Peripheral Neuropathy, Tomaculous Neuropathy, Spinal Muscular Atrophy with Arthrogryposis, and Prostatectomy. Dr. Hoke is board certified in American Board Of Psychiatry And Neurology.

Dr. Rafael Llinas serves as the Director of Neurology at the Johns Hopkins Bayview Medical Center. His clinical interests include acute stroke treatments, neurovascular imaging and migraine as related to cerebrovascular disease. He also serves as the associate director of the neurology residency program. He was instrumental in establishing the Johns Hopkins Bayview Medical Center Stroke Center. In 2005, in recognition of the Stroke Centers organizational efforts in stroke care, the institution was granted certification as a Primary Stroke Center by the Joint Commission on Accreditation of Healthcare Organizations. Dr. Llinas primary areas of research interests include diffusion-perfusion imaging of stroke, intravenous and intra-arterial thrombolysis for stroke, education of physicians and nurses in stroke identification and stroke care, stroke units and stroke centers. Dr. Rafael Llinas received his medical degree from the New York University School of Medicine. He completed a medical internship at the Boston City Hospital and was a neurology resident in the Harvard-Longwood neurology training program. Following his residency, he was a stroke and cerebrovascular disease fellow for two years at Beth Israel Hospital, Harvard University. Dr. Llinas is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Stroke, Cerebral Amyloid Angiopathy, Siderosis, Thrombectomy, and Gastrostomy. Dr. Llinas is board certified in American Board Of Psychiatry And Neurology.

Dr. Tom Crawford has been a member of the Department of Neurology since 1987. He is co-director of the MDA clinic for Neuromuscular Disorders and Neurologist for the Ataxia Telangiectasia Clinical Center at Johns Hopkins. His practice involves general child neurology with a principal interest in caring for children with neuromuscular, neuromotor, and ataxic disorders. Primary research interests involve the basic science and clinical characterization of two important neurologic disorders that affect children: Spinal Muscular Atrophy and Ataxia Telangiectasia. He is also actively involved in the Biology of neurofilaments by characterization of transgenic animal models. He is on the Medical and Scientific Advisory Boards of Families of Spinal Muscular Atrophy, and the Medical Advisory Committee for the Muscular Dystrophy Association. He is the Neurologist for the Ataxia Telangiectasia Clinical Center at Johns Hopkins, which has evaluated almost half of the known patients with this disorder in the United States. Additional specific clinical interests include evaluation and treatment of children with brachial plexus palsies. Dr. Crawford received his medical degree from the University of Southern California. He completed a pediatric internship and residency at the Pediatric Pavilion of the Los Angeles County / University of Southern California Medical Center, followed by a pediatric chief residency. He completed his training in Neurology with Special Qualification in Child Neurology at the Los Angeles Childrens Hospital. He then traveled east to the laboratory of Dr John Griffin at Johns Hopkins for a fellowship in Neuromuscular Disorders. Prior to medical training and Neurology residency, he majored in Psychology and Religion at Yale College. Dr. Crawford has published extensively and presented nationally and internationally. He has an active role in teaching medical students and residents in neurology. In addition, Dr. Crawford has special interest and experience in EMG studies of children and adults. Dr. Crawford is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), Ataxia-Telangiectasia, and Spinal Muscular Atrophy Type 2. Dr. Crawford is board certified in American Board Of Psychiatry And Neurology and American Board Of Pediatrics.

Carlos Romo, M.D., is a neuro-oncologist in Baltimore, Maryland. Dr. Romo specializes in the diagnosis and treatment of brain tumors, including glioblastoma, astrocytomas, oligodendrogliomas, neurofibromas, and schwannomas among others. Dr. Romo earned his medical degree from the School of Medicine and Health Sciences at Tecnológico de Monterrey in Mexico and completed his Neurology residency at the University of Arkansas for Medical Sciences, where he served as chief resident. He then completed a Neuro-oncology clinical and research fellowship in a joint program between The Johns Hopkins University and the National Institutes of Health. Dr. Romo additionally trained as a clinical pharmacology fellow at The Johns Hopkins University and completed training on clinical cancer research at the University of Texas MD Anderson Cancer Center. In his research, Dr. Romo studies drug pharmacokinetics and the blood-brain barrier, and investigates better ways to reach tumors in the central nervous system. Dr. Romo also studies treatments for patient with neurofibromatosis. In addition to patient care and research, Dr. Romo teaches and mentors medical and undergraduate students to help develop a future generation of neurologists. Dr. Romo is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Schwannomatosis, and Astrocytoma. Dr. Romo is board certified in American Board Of Psychiatry And Neurology.

With fellowship training in neuro-ophthalmology and additional training in neuro-vestibular disorders, Dr. Daniel Gold sees patients with neuro-ophthalmic disorders (affecting vision, eyelids, pupils, or causing nystagmus or double vision) in addition to oto-neurologic disorders (causing dizziness and vertigo). Videos 2018 Best Consulting Physician Award Tele-(Dizzy) Medicine. Dr. Gold is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Vertigo, Benign Paroxysmal Positional Vertigo, Brown Syndrome, and Stiff Person Syndrome. Dr. Gold is board certified in American Board Of Psychiatry And Neurology.

Dr. Argye Hillis is a professor of Neurology, with joint faculty appointments in Physical Medicine and Rehabilitation and in Cognitive Science. She is also the Sheikh Khalifa Stroke Institute Professor of Acute Stroke Diagnoses and Management. Prior to medical training and neurology residency, Dr. Hillis worked as a speech-language pathologist, and conducted clinical research focusing on understanding and treating aphasia and hemispatial neglect. She has brought these areas of experience to impact on her clinical research in neurology, which involves cognitive and neuroimaging studies of aphasia and hemispatial neglect due to acute stroke and focal dementias. She has published extensively on these topics in journals and textbooks. Dr. Hillis is Associate Editor of Stroke and has served as Associate editor of Brain, Annals of Neurology, Aphasiology, American Journal of Speech-Language Pathology, Neurocase, Cognitive Neuropsychology, and Language and Cognitive Processes and served as co-Editor and Chief of Behavioral Neurology. Dr. Hillis serves as the Executive Vice Chair of the Department of Neurology and the Director of the Cerebrovascular Division of Neurology at Johns Hopkins. Dr. Hillis is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Primary Progressive Aphasia, Stroke, Frontotemporal Dementia, Thrombectomy, and Gastrostomy. Dr. Hillis is board certified in American Board Of Psychiatry And Neurology.

Dr. Gregory Krauss focuses on the evaluation and treatment of seizures and epilepsy. He has a particular interest in treating medically-resistant epilepsy, evaluating unexplained seizure-like episodes, treating seizures associated with tumor and systemic illnesses and family planning counseling for patients with epilepsy. Dr. Krauss also evaluates patients who have failed standard medical therapies for possible treatment with epilepsy surgery, investigational medications or vagal nerve stimulation. Dr. Gregory Krauss received his medical degree from Oregon Health Sciences University. He then completed an internship in medicine at Greenwich Hospital. He went on to complete both a residency in neurology and a fellowship in epilepsy and electrophysiology at The Johns Hopkins Hospital. Dr. Krauss currently sees patients at The Johns Hopkins Outpatient Center in Baltimore on Tuesdays and Wednesdays. Dr. Krauss is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Seizures, Generalized Tonic-Clonic Seizure, Epilepsy, and Absence Seizure. Dr. Krauss is board certified in American Board Of Psychiatry And Neurology.

Dr. Nathan Crone focuses on the diagnosis and treatment of seizures and epilepsy, including the surgical treatment of epilepsy. He is also one of the attending physicians in the Epilepsy monitoring unit. Dr. Crone''s research interests include the real-time mapping of brain function to reduce the possibility of impacting brain function during surgery for epilepsy. He received his medical degree from Louisiana State University School of Medicine. He then completed his residency in neurology at the University of Chicago and fellowships in epilepsy and cognitive neurology at Johns Hopkins. Dr. Crone is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Seizures, Epilepsy, Generalized Tonic-Clonic Seizure, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Deep Brain Stimulation. Dr. Crone is board certified in American Board Of Psychiatry And Neurology.

Dr. Mackenzie Cervenka focuses on the diagnosis and treatment of patients with seizures and epilepsy, including surgical treatment and dietary therapies. She is an attending physician in the Epilepsy Monitoring Unit. Her specific interests include evaluations for seizure surgery, continuous electroencephalography in the intensive care unit, epilepsy in women (including considerations during pregnancy), and dietary therapies for adults with epilepsy. Dr. Cervenka's research focuses the efficacy of Ketogenic diets in the treatment of adults with epilepsy. She also studies brain mapping in preparation for epilepsy surgery. Dr. Cervenka completed her undergraduate studies at the University of Virginia and received her medical degree from the University of Virginia School of Medicine. She then completed her internship in internal medicine and residency in neurology at the University of Maryland Medical Center. Dr. Cervenka completed a fellowship in epilepsy and clinical neurophysiology at Johns Hopkins. Dr. Cervenka currently sees patients in The Johns Hopkins Outpatient Center on Monday and Wednesday afternoons. She also sees patients in The Johns Hopkins Adult Epilepsy Diet Center on Friday mornings once a month. Dr. Cervenka is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Epilepsy, Seizures, Lennox-Gastaut Syndrome (LGS), and Status Epilepticus. Dr. Cervenka is board certified in American Board Of Psychiatry And Neurology.

Dr. Elisabeth Marsh's clinical interest is in cerebrovascular neurology, and her clinical research focuses on stroke outcomes and recovery. Her clinical responsibilities include attending on the inpatient Stroke Service at the Johns Hopkins Hospital and inpatient Neurology Service at the Johns Hopkins Bayview Medical Center. In 2014, Dr. Marsh was named the Medical Director of the Comprehensive Stroke Program at the Johns Hopkins Bayview Medical Center. She implemented the Bayview Stroke Intervention Clinic (BaSIC), a multi-disciplinary follow-up clinic designed to promote patient follow-up, reduce hospital readmission rates, and enhance post-stroke recovery. Her current focus is on the under-reported neurologic deficits (particularly with respect to depression, fatigue, and cognition) that significantly impair long-term functional outcome and patient satisfaction, despite scores on metrics such as the NIH stroke scale that indicate a “good recovery”. She leads a team of vascular neurologists, emergency medicine physicians, neurosurgeons, interventional neuroradiologists, neurointensivists, and rehabilitation specialists, who work together to provide the highest level of care to all stroke patients, resulting in better functional outcomes and improved quality of life. She is also interested in the treatment of acute stroke and intracranial hemorrhage. Her past work has included evaluation of the predictors of hemorrhagic transformation following ischemic stroke. Using multivariable regression, she created a model that predicts rate of hemorrhagic transformation in patients with acute stroke on anticoagulation, the Hemorrhage Risk Stratification (HeRS) score. The tool is available for free through Apple by searching 'Johns Hopkins HeRS score' in the App Store. Dr. Marsh is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Stroke, Apoplexy, Transient Ischemic Attack (TIA), Thrombectomy, and Gastrostomy. Dr. Marsh is board certified in American Board Of Psychiatry And Neurology.

Dr. Christopher Earley's research and clinical interests are devoted to Sleep Medicine with a special interest in Restless Legs Syndrome. His current research is focused on understanding the pathophysiology of Restless Legs Syndrome and further elucidating the value of various treatments in this syndrome. Dr. Earley received his medical degree as well as a PhD in Pharmacology from the University College in Galway, Ireland. He completed a full residency in Internal Medicine at Baylor Medical College and then went to the University of Virginia in Charlottesville to complete his residency in Neurology. After then spending a year at the NIH as a fellow in the Neurobiology Unit, Dr. Earley joined the faculty at Johns Hopkins in 1991. 2008 Professor, Department of Neurology, Johns Hopkins 1994- Associate Director, Sleep Disorders Center, JHBMC Education and Training: 1973 - B.S. (General), Villanova University 1974 - B.A. (Psychology), Arizona State University 1978 - Ph.D. (Pharmacology), National University of Ireland 1983 - M.B., B.Ch. ( Medicine), National University of Ireland 1983-1984 Internship, University Hospital, Galway, Ireland 1984-1987 Resident in Internal Medicine, Baylor College of Medicine, Houston, TX 1987-1990 Resident in Neurology, University of Virginia, Charlottesville, VA 1990-1991 Senior Staff Fellow, Neurobiology Unit, NIH/NIA Professional Experience: 1991- Full-time Staff Neurologist, Johns Hopkins 1992-1999 Assistant Professor, Department of Neurology, Johns Hopkins 1993-2001 Director, Acute Stroke Service, 1994- Associate Director, Sleep Disorders Center 1994-1999 Co-Director, Neurosciences Critical Care Unit 1996-2000 Director, Neurovascular Ultrasound Lab 1999-2008 Associate Professor, Department of Neurology, Johns Hopkins. Dr. Earley is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Restless Legs Syndrome, Periodic Limb Movement Disorder, Narcolepsy, Seizures, and Gastrostomy. Dr. Earley is board certified in American Board Of Psychiatry And Neurology and American Board Of Internal Medicine.

1988-1992, Assistant Professor, Department of Pharmacology, Semmelweis Medical University, Budapest, Hungary. 1992-1996, Instructor, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. 2001-2014, Assistant Professor, Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, MD. 2012-2014, Assistant Professor, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD. 2014-present, Associate Professor, Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Baltimore, MD. 2014-present, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD. Dr. Yasar is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Normal Pressure Hydrocephalus, Congenital Cardiovascular Shunt, Dementia, and Alzheimer's Disease. Dr. Yasar is board certified in American Board Of Internal Medicine.

Dr. Mowry became interested in multiple sclerosis (MS) prior to beginning college and first performed MS research as an undergraduate biology major at Georgetown University. As a neurology resident at the University of Pennsylvania, she began her multiple sclerosis clinical research activities in conducting a study of visual dysfunction and quality of life in multiple sclerosis. During her fellowship at UCSF, Dr. Mowry evaluated prognostic factors in multiple sclerosis and examined health-related quality of life in multiple sclerosis, particularly as a marker of disease burden. She also earned a Master’s Degree in Clinical Research at UCSF. Dr. Mowry continued as a member of the faculty there before joining the Johns Hopkins Department of Neurology as an Assistant Professor in July, 2011; she received a joint appointment in Epidemiology in 2013. She was appointed as the inaugural Richard T. and Frances W. Johnson Professor in 2022. Over the past several years, Dr. Mowry has worked primarily to perform epidemiologic investigations of multiple sclerosis (MS) risk and prognostic factors and has evaluated both genetic and environmental contributors. While she has had a major role in several such studies, her most significant work led to the identification of the association of vitamin D status with relapse and brain lesion risk in patients with MS (Annals of Neurology 2010, Annals of Neurology 2012, European Journal of Neurology 2015). She also conducted the first pilot study comparing gut bacterial populations in patients with MS and healthy individuals (Journal of Investigative Medicine 2014). She was recently funded to investigate the impact of vitamin D supplementation on the metabolomics profile in patients with MS compared to healthy controls. She enjoys designing and conducting clinical trials in MS and is the Principal Investigator of the Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) multicenter vitamin D trial (NCT01490502), which is sponsored by the National MS Society and a smaller multicenter pilot study investigating vitamin D pharmacokinetics in MS patients and healthy controls (NCT01667796). She is also the recipient of a Harry Weaver Award from the National MS Society, in which she is investigating the impact of intermittent calorie restriction in MS. Finally, as Director of the MS Experimental Therapeutics Program at Johns Hopkins, she assists colleagues with study design and helps oversee the conduct of MS clinical trials. Dr. Mowry is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), Optic Neuritis, and Neuromyelitis Optica. Dr. Mowry is board certified in American Board Of Psychiatry And Neurology.

Dr. Emily Johnson focuses on the diagnosis and treatment of epilepsy and seizures. Dr. Johnson has a clinical interest in women of childbearing age with epilepsy. Her research interests also include new-onset, unexplained seizures in older adults. Dr. Johnson received her medical degree from Johns Hopkins. She trained in Neurology at Harvard - Massachusetts General Hospital/Brigham and Women’s Hospital, and completed training in Epilepsy at Johns Hopkins. Dr. Johnson is an Associate Editor for the journal Neurology. Dr. Johnson is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Seizures, Epilepsy, Absence Seizure, Thrombectomy, and Endovascular Embolization. Dr. Johnson is board certified in American Board Of Psychiatry And Neurology.

A leading expert on brain injury, Dr. Daniel F. Hanley has been a professor of neurology, neurosurgery, and anesthesiology/critical care medicine at the Johns Hopkins University School of Medicine since 1996 and was named the Jeffrey and Harriet Legum Chair of Acute Care Neurology. Dr. Hanley founded and directed the Johns Hopkins Neurocritical Care Unit, one of the first critical care units dedicated solely to neurosurgical and neurological patients. Subsequently, in 1999, he founded and continues to direct the BIOS Clinical Trials Coordinating Center (BIOS CTCC), formerly known as the Division of Brain Injury Outcomes. Under Dr. Hanley’s leadership, BIOS CTCC, an academic contract research organization based at Johns Hopkins, has organized and completed more than 20 large clinical trials. He has been awarded over 70 clinical and basic research grants, predominantly from the National Institutes of Health and the FDA Orphan Products Grants Program. Dr. Hanley’s 40-year career in medicine has focused on clinical trial design, the organization and interpretation of drug and device trials, the development of strategic research plans, and FDA regulatory compliance. He has led international, NIH-sponsored trials including the MISTIE III and CLEAR III trials investigating minimally invasive neurosurgical techniques to treat hemorrhagic stroke. As principal investigator for the National Center for Advancing Translational Sciences (NCATS) Johns Hopkins Trial Innovation Center, Dr. Hanley leads collaborative efforts to advance education and therapeutics through innovative CTSA clinical trials. Currently, Dr. Hanley is the PI or multi-PI for several ongoing trials. These include a multisite phase 2/3 randomized controlled dementia prevention trial (MAP), a large multicenter clinical trial involving automated monitoring of atrial fibrillation (REACT AF), and a first-in-patient phase 2a biomarker and edema attenuation in intracerebral hemorrhage trial (BEACH). Dr. Hanley has published over 400 peer-reviewed articles and book chapters, received the Humboldt Research Prize for accomplishments in brain injury research, and mentored nearly 100 researchers. His trainees, which include a large number of trialists, have led 25 brain intensive care units, and over 40 have been named full professors, program leaders, or department chairs. He has served on public boards including the American Academy of Neurology, National Stroke Association, and NIH National Institute of Nursing Research. Dr. Hanley is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Stroke, Hydrocephalus, Vertigo, Thrombectomy, and Gastrostomy. Dr. Hanley is board certified in American Board Of Psychiatry And Neurology and American Board Of Internal Medicine.

Bardia Nourbakhsh, M.D., M.A.S., is an associate professor of neurology at Johns Hopkins University School of Medicine. He practices out of The Johns Hopkins Hospital in Baltimore, Maryland. Dr. Nourbakhsh has expertise in multiple sclerosis (MS) and neuroimmunology. Dr. Nourbakhsh earned his medical degree from the Tehran University School of Medical Sciences and completed a residency in neurology at the University of Texas Southwestern Medical Center. He studied epidemiology, study design, and biostatistics, obtaining a Master of Advanced Studies degree in clinical research from the University of California, San Francisco School of Medicine, where he also completed a fellowship in MS and neuroimmunology. In 2014, Dr. Nourbakhsh earned the American Brain Foundation Clinical Research Training Fellowship in MS, the National Multiple Sclerosis Society Sylvia Lawry Clinical Research Fellowship, the Fred Baskin Young Investigator Award, and the Teva Neuroscience Award for Academic Excellence. In 2022, he was named a Harry Weaver Neuroscience Scholar by the National Multiple Sclerosis Society. Dr. Nourbakhsh's research training focused on the design and execution of clinical trials and the use of biomarkers in MS. His current research interests include the comparative effectiveness studies of symptomatic and disease-modifying therapies in MS, as well as identifying new pathophysiologic mechanisms and therapeutic targets for MS-related fatigue. Dr. Nourbakhsh is the principal investigator of a randomized, double-blind clinical trial funded by the Department of Defense, which tests whether ketamine could be a treatment for MS fatigue. He has contributed to numerous publications, journal articles, abstracts and posters, and lectures. He is an ad hoc reviewer for Lancet Neurology, Annals of Neurology, Neurology, Neurology: Neuroimmunology and Neuroinflammation, Multiple Sclerosis Journal, and other journals. Dr. Nourbakhsh is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, and Meningocele. Dr. Nourbakhsh is board certified in American Board Of Psychiatry And Neurology.

Dr. Bhargava developed an interest in immunology early in medical school at the Christian Medical College in Vellore, India. He then completed his neurology training at the Southern Illinois University School of Medicine and while there began research in the field of multiple sclerosis (MS). Following his neurology training he completed a 3-year fellowship at the Johns Hopkins University in neuroimmunology and neurological infections focusing on MS clinical care and research. His fellowship training was supported by a Sylvia Lawry physician fellowship award from the National MS Society. His main research interests include studying the role of inflammation in the meninges in progression of MS disease. He is currently involved in a trial testing the utility of injecting a drug called rituximab into the spinal fluid in patients with progressive MS. He is also developing an animal model of the process of meningeal inflammation to test other potential treatments. This work is supported by awards from the National MS Society, Race to Erase MS and the American Academy of Neurology. He is also actively involved in studying the role of measuring lipids and small molecule metabolites in serum and plasma to help identify new biomarkers for improved diagnosis and prognosis of the disease. These methods could also help in better tracking the effects of various interventions and in personalizing the treatment of patients with MS. Dr. Bhargava is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), CACH Syndrome, and Transverse Myelitis. Dr. Bhargava is board certified in American Board Of Psychiatry And Neurology.